ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Crucial Innovations Corp. Appoints Rory Bowen to its Board of Directors

Seasoned finance and innovation executive brings global strategy and governance expertise to support CINV’s mission of advancing medicinal cannabis accessibility across the UK and Europe

LONDON , Nov. 18, 2025 (GLOBE NEWSWIRE) -- Crucial Innovations Corp., a pioneering medical cannabis company, announced the appointment of Rory Bowen to its Board of Directors, effective immediately.

Mr. Bowen is a seasoned executive, investor and strategist with extensive experience spanning finance, technology and global innovation. He currently serves as Chief of Staff at Hermitage Holdings, a global investment company; Principal and Founder of Circus Capital; Principal at Outsize Capital; and Non-Executive Director at Kadoma Mining PLC.

With a proven track record of driving strategic growth and organizational transformation, Mr. Bowen brings multidisciplinary expertise in corporate finance, capital markets and governance. He has worked alongside CEOs, boards and senior leadership teams to implement high-impact operational frameworks that balance innovation with disciplined execution.

“Rory’s appointment reflects our commitment to bringing visionary, globally minded leaders onto our Board,” said Crucial Innovations Corp. CEO JP Doran. “His deep understanding of capital markets, strategic partnerships and international business development will strengthen CINV’s mission to advance the accessibility and integrity of cannabis-based medicines across the UK and Europe.”

Adding Rory to the Board as an independent director is reflective of the Company’s intention to meet Nasdaq’s corporate governance standards by having a majority of independent directors on the Board.

Mr. Bowen began his career in financial markets with Moneycorp and Compagnie Financière Tradition (Tradition UK), before transitioning into strategic leadership at FinTech Alliance, an organization established in partnership with the UK Department for International Trade. There, he helped shape the UK’s national FinTech growth and investment agenda, representing the British Government on international trade missions and engaging with global policymakers.

His subsequent leadership roles across Europe, Africa and the Middle East have provided him with deep cross-cultural insight into emerging markets, M&A strategy and regulatory navigation—skills that will contribute significantly to CINV’s evolving international footprint.

“Crucial Innovations is setting new standards for the cultivation and delivery of cannabis-based products for medicinal use,” said Bowen. “I am honoured to join the Board at this pivotal moment and look forward to supporting the company’s mission to deliver safe, effective and ethically produced Cannabis-Based Products for Medicinal Use (CBPMs) through a truly global seed-to-heal model.”

About Crucial Innovations Corp. (CINV)
Crucial Innovations Corp. (OTC: CINV) is a pioneering medical cannabis company. With a fully licensed network of esteemed cultivators, CINV delivers carefully curated cannabis to the medicinal market in the UK and Europe through its vertically integrated seed-to-sale process. At CINV, we are establishing a new standard for cultivating high-quality cannabis-based products for medicinal use (CBPMs), ensuring consistency, safety, and accessibility across the global supply chain. For more information, please visit www.cinvcorp.com.

Media Contact:
cinv@kcsa.com


Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.69
+3.55 (1.63%)
AAPL  271.49
+5.24 (1.97%)
AMD  203.78
-2.24 (-1.09%)
BAC  51.56
+0.56 (1.10%)
GOOG  299.65
+9.67 (3.33%)
META  594.25
+5.10 (0.87%)
MSFT  472.12
-6.31 (-1.32%)
NVDA  178.88
-1.76 (-0.97%)
ORCL  198.76
-11.93 (-5.66%)
TSLA  391.09
-4.14 (-1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.